RAD April 2022 Conference Abstracts and Posters
236 - Impact of Crisaborole in Patients With Mild-to-Moderate Atopic Dermatitis Who Received Prior Treatment
Linda Stein Gold, Vivian Shi, Bonnie Vlahos, Paul Sanders, Chuanbo Zang, Amy Cha
237 - History of atopic dermatitis is associated with different characteristics and etiologies among patients with hand eczema referred for patch testing in North America
Nisha Patel BS; Jonathan I. Silverberg, MD; Erin M. Warshaw, MD, MS; Amber R. Atwater, MD; Howard I. Maibach, MD; Kathryn A. Zug, MD; Margo J. Reeder, MD; Denis Sasseville, MD; James S. Taylor, MD; Joseph F. Fowler, Jr, MD; Melanie D. Pratt, MD; Donald V. Belsito, MD; Vincent A. DeLeo, MD and Joel G. DeKoven, MD
238 - Effect of Abrocitinib on Individual Signs of Atopic Dermatitis Assessed by Eczema Area and Severity Index (EASI) Subscores
Andrew Blauvelt, Peter A. Lio, Melinda J. Gooderham, James Q. Del Rosso, Leon Kircik, Ama Alexis, Jacob P. Thyssen, Gary Chan, Pinaki Biswas, Urs Kerkmann, Daniela E. Myers, Mark Levenberg
239 - Multidomain Responses to Abrocitinib 100 mg With or Without Background Topical Medications in Adults With Atopic Dermatitis: A Post Hoc Analysis
Eric Simpson, Raj Chovatiya, Peter Schmid-Grendelmeier, Irina Lazariciu, Daniela E. Myers, Claire Clibborn
240 - Effects of Ruxolitinib Cream on Patient-Reported Quality of Life in Atopic Dermatitis: 52-Week Pooled Results from Two Phase 3 Studies
Eric L. Simpson, MD, MCR, Jonathan I. Silverberg, MD, PhD, MPH, April W. Armstrong, MD, MPH, Zelma C. Chiesa Fuxench, MD, MSCE, May E. Venturanza, MD, Howard Kallender, PhD, Jessy Gao, MA, Leon Kircik, MD
241 - Long-term improvements in disease severity, itch, and quality of life after 3 years of tralokinumab treatment in adults with moderate-to-severe atopic dermatitis
Richard Langley, Kristian Reich, Eric Simpson, Richard B Warren, Antonio Costanzo, Hidehisa Saeki, Stine Fangel, Nathan Lassota, Anna Carlsson, Melinda Gooderham, Jean Philippe Lacour, Juan Francisco Silvestre, Andreas Pinter, Andrew Blauvelt
242 - High-Level Responses Across Multiple Domains in Patients With Atopic Dermatitis Treated with Abrocitinib versus Dupilumab: A Post Hoc Analysis of a Phase 3 Randomized Trial
April W. Armstrong, Andrew Blauvelt, Melinda J. Gooderham, H. Chih-ho Hong, Fan Zhang, Claire Feeney, Claire Clibborn, Daniela E. Myers, Gary Chan
243 - Effects of Ruxolitinib Cream on Work Productivity and Activity Impairment in Patients With Atopic Dermatitis: 52-Week Pooled Results From Two Phase 3 Studies
Lawrence F. Eichenfield, MD, Matthias Augustin, MD, April W. Armstrong, MD, MPH, May E. Venturanza, MD, Howard Kallender, PhD, Jessy Gao, MA, Jonathan I. Silverberg, MD, PhD, MPH
244 - Epidemiology and Clinical Presentation of Pediatric-onset vs. Adult-onset Atopic Dermatitis
Munayco Maldonado, G.M., BS; Foy, V.M., BS; Chiesa Fuxench, Z.C., MD, MSCE
245 - Long-term efficacy and safety of etrasimod, an oral, selective sphingosine 1-phosphate receptor1,4,5 modulator, for moderate-to-severe atopic dermatitis: Results from the open-label extension of the Phase 2 ADVISE study
Emma Guttman-Yassky, Robert Bissonette, Leon Kircik, Dedee Murrell, Fiona I. Kuo, Kris Liu, Gurpreet Ahluwalia, Jonathan I. Silverberg